Ten years of tiotropium: Clinical impact and patient perspectives

International Journal of COPD

Volumn 8, Issue , 2013, Pages 117-125

  Yohannes, Abebaw M ^a   Connolly, Martin J ^b   Hanania, Nicola A ^c  

^a MANCHESTER METROPOLITAN UNIVERSITY   (United Kingdom)

^b UNIVERSITY OF AUCKLAND   (New Zealand)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Bronchodilator; Chronic obstructive pulmonary disease; Indacaterol; LABA; Salmeterol; Tiotropium

Indexed keywords

ACLIDINIUM BROMIDE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE PLUS FORMOTEROL; CHOLINERGIC RECEPTOR BLOCKING AGENT; FLUTICASONE PROPIONATE PLUS SALMETEROL; FORMOTEROL; GLYCOPYRRONIUM BROMIDE; INDACATEROL; IPRATROPIUM BROMIDE; IPRATROPIUM BROMIDE PLUS SALBUTAMOL; LONG ACTING DRUG; PLACEBO; SALBUTAMOL; SALMETEROL; TIOTROPIUM BROMIDE; VILANTEROL;

ANGINA PECTORIS; ANTICHOLINERGIC SYNDROME; BLURRED VISION; CARDIOVASCULAR DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONSTIPATION; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; EVIDENCE BASED MEDICINE; FOLLOW UP; HOSPITALIZATION; HUMAN; INHALER; INTRAOCULAR PRESSURE; PATIENT COMPLIANCE; QUALITY OF LIFE; REVIEW; SIDE EFFECT; TACHYCARDIA; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; URINE RETENTION; XEROSTOMIA;

BRONCHODILATOR; CHRONIC OBSTRUCTIVE PULMONARY DISEASE; INDACATEROL; LABA; SALMETEROL; TIOTROPIUM;

ADRENERGIC BETA-2 RECEPTOR AGONISTS; ALBUTEROL; BRONCHODILATOR AGENTS; DYSPNEA; ETHANOLAMINES; HUMANS; INDANS; MEDICATION ADHERENCE; MUCOCILIARY CLEARANCE; NEBULIZERS AND VAPORIZERS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUALITY OF LIFE; QUINOLONES; SCOPOLAMINE DERIVATIVES;

EID: 84875198162     PISSN: 11769106     EISSN: 11782005     Source Type: Journal    
DOI: 10.2147/COPD.S28576     Document Type: Review

References (46)

1. World Health Organization. COPD predicted to be third leading cause of death in 2030 [webpage on the Internet]. Geneva: World Health Organization; 2008. Available from: http://www.who.int/respira-tory/copd/World_Health_Statistics_2008/en/index.html. Accessed February 12, 2013.
2. Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 2007;3(11):e442.
3. US Department of Health and Human Services. National Institutes of Health. National Heart Lung and Blood Institute. Morbidity and Mortality: 2009 Chart book on Cardiovascular, Lung and Blood Diseases. [webpage on the Internet]. Available from: http://www.nhlbi.nih.gov/about/factbook-09/chapter4.htm. Accessed February 12, 2013.
4. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of COPD [webpage on the Internet]. Vancouver, WA: Global Initiative for Chronic Obstructive Lung Disease; 2011 [updated Dec 2011]. Available from: http://www.goldcopd.org/uploads/users/fles/GOLD_Report_2013.pdf. Accessed February 12, 2013.
5. National Institute for Health and Clinical Excellence. Chronic Obstructive Pulmonary Disease: Management of Chronic Obstructive Pulmonary Disease in Adults in Primary and Secondary Care. London: National Clinical Guideline Centre; 2010. Available from: http://guidance.nice.org.uk/CG101/Guidance/pdf/English. Accessed February 12, 2013.
6. Vogelmeier C, Hederer B, Glaab T, et al; For POET-COPD Investigators. Tiotropium versus salmeterol for the prevention of exacerbations of COPD. N Engl J Med. 2011;364(12):1093-1103.
7. Calverley PM, Anderson JA, Celli B, et al; For Torch investigators. Salmeterol and fucticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 2007;356(8): 775-789.
8. Tashkin DP, Celli B, Senn S, et al; For UPLIFT Study Investigators. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med. 2008;359(15):1543-1554.
9. Wedzicha JA, Calverley PM, Seemungal TA, Hagan G, Ansari Z, Stockley RA; For INSPIRE Investigators. The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/futicasone propionate or tiotropium bromide. Am J Respir Crit Care Med. 2008;177(1):19-26.
10. Aaron SD, Vandehmheen KL, Fergusson D, et al; For Canadian Thoracic Society/Canadian Respiratory Clinical Research Consortium. Tiotropium in combination with placebo, salmeterol, or futicasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med. 2007;146(8):545-555.
11. Bourbeau J, Bartlett SJ. Patient adherence in COPD. Thorax. 2008; 63(9):831-838.
12. Boehringer Ingelheim GmbH. Annual Report 2011. Ingelheim: Boehringer Ingelheim GmbH; 2011. Available from: http://www.boehringer-ingelheim.com/content/dam/internet/opu/com_EN/document/01_news/08_APC/APC_2012/BoehringerIngelheim_Annual_Report_2011_complete.pdf. Accessed November 8, 2012.
13. Barr RG, Bourbeau J, Camargo CA, Ram FS. Tiotropium for stable chronic obstructive pulmonary disease: a meta-analysis. Thorax. 2006; 61(10):854-862.
14. Kesten S, Jara M, Wentworth C, Lanes S. Pooled clinical trials analysis of tiotropium safety. Chest. 2006;130(6):1695-1703.
15. Singh S, Loke YK, Furberg CD. Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. JAMA. 2008;300(12):1439-1450.
16. Celli B, Decramer M, Leimer I, Vogel U, Kesten S, Tashkin D P. Cardiovascular safety of tiotropium in patients with COPD. Chest. 2010; 137(1):20-30.
17. Halpin D, Menjoge S, Viel K. Patient-level pooled analysis of the effect of tiotropium on COPD exacerbations and related hospitalisations. Prim Care Respir J. 2009;18(2):106-113.
18. Yohannes AM, Willgoss TG, Vestbo J. Tiotropium for treatment of stable COPD: a meta-analysis of clinically relevant outcomes. Respir Care. 2011;56(4):477-487.
19. Singh S, Loke YK, Enright PL, Furberg CD. Mortality associated with tiotropium mist inhaler in patients with chronic obstructive pulmonary disease: systematic review and meta-analysis of randomised controlled trials. BMJ. 2011;342:d3215.
20. Dong YH, Lin HH, Shau WY, Wu YC, Chang CH, Lai MS. Comparative safety of inhaled medications in patients with chronic obstructive pulmonary disease: systematic review and mixed treatment comparison meta-analysis of randomised controlled trials. Thorax. 2013;68(1):48-56.
21. Karner C, Chong J, Poole P. Tiotropium versus placebo for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2012; 7:CD009285.
22. Chong J, Karner C, Poole P. Tiotropium versus long-acting beta-agonists for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2012;9:CD009157.
23. Barnes PJ. The role of anticholinergics in chronic obstructive pulmonary disease. Am J Med. 2004;117 Suppl 12A:24S-32S.
24. Baterman ED, Rennard S, Barnes PJ, et al. Alternative mechanisms for tiotropium. Pulm Pharmacol Ther. 2009;22(6):533-542.
25. Novelli F, Malagrinò L, Dente FL, Paggiaro P. Efficacy of anti-cholinergic drugs in asthma. Expert Rev Respir Med. 2012;6(3): 309-319.
26. Belmonte KE. Cholinergic pathways in the lungs and anticholinergic therapy for chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2005;2(4):297-304.
27. Gosens R, Zaggsma J, Meurs H, Halayko J. Muscarine receptor signaling in the pathophysiology of asthma and COPD. Respir Res. 2006;7:73.
28. Arai N, Kondo M, Izumo T, Tamaoki J, Nagai A. Inhibition of neu-trophil elastase-induced goblet cell metaplasia by tiotropium in mice. Eur Respir J. 2010;35(5):1164-1171.
29. Hasani A, Toms N, Agnew JE, Sarno M, Harrison AJ, Dilworth P. The effect of inhaled tiotropium bromide on lung mucociliary clearance in patients with COPD. Chest. 2004;125(5):1726-1734.
30. Meyer T, Reitmeir P, Brand P, et al. Effects of formoterol and tiotro-pium bromide on mucus clearance in patients with COPD. Respir Med. 2011;105(6):900-906.
31. Brusasco V, Hodder R, Miravitlles M, Korducki L, Towse L, Kesten S. Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD. Thorax. 2003;58(5):399-404.
32. Casaburi R, Mahler DA, Jones P W, et al. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J. 2002;19(2):217-224.
33. Briggs DD Jr, Covelli H, Lapidus R, Bhattycharya S, Kesten S, Cassino C. Improved daytime spirometric efficacy of tiotropium compared with salmeterol in patients with COPD. Pulm Pharmacol Ther. 2005;18(6):397-404.
34. van Noord JA, Aumann JL, Janssens E, et al. Comparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPD. Eur Respir J. 2005;26(2):214-222.
35. Hanania NA, Boota A, Kerwin E, Tomlinson L, Denis-Mize K. Efficacy and safety of nebulized formoterol as add-on therapy in COPD patients receiving maintenance tiotropium bromide: Results from a 6-week, randomized, placebo-controlled, clinical trial. Drugs. 2009;18:69(9):1205-1216.
36. Donohue JF, Fogarty C, Lötvall J, et al; For INHANCE Study Investigators. Once-daily bronchodilators for chronic obstructive pulmonary disease: indaceterol versus tiotropium. Am J Respir Crit Care Med. 2010;182(2):155-162.
37. Buhl R, Dunn LJ, Disdier C, et al; For INTENSITY study investigators. Blinded 12-week comparison of once-daily indacaterol and tiotropium in COPD. Eur Respir J. 2011;38(4):797-803.
38. Kerwin E, Hébert J, Gallagher N, et al. Efficacy and safety of NVA237 versus placebo and tiotropium in patients with COPD: the GLOW2 study. Eur Respir J. 2012;40(5):1106-1114.
39. Jara M, Wentworth C 3rd, Lanes S. A new user cohort study comparing the safety of long-acting inhaled bronchodilators in COPD. BMJ Open. 2012;2(3):e000841.
40. Medicines and Healthcare Products Regulatory Agency. Tiotropium. Safety studies of Spiriva Respimat. 2010. Available from http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON099869. Accessed February 12, 2013.
41. Wilt TJ, Niewoehner D, MacDonald R, Kane RL. Management of stable chronic obstructive pulmonary disease: a systematic review for a clinical practice guideline. Ann Intern Med. 2007;147(9):639-653.
42. Oba Y, Zaza T, Thameem DM. Safety, tolerability and risk beneft analysis of tiotropium in COPD. Int J Chron Obstruct Pulmon Dis. 2008;3(4):575-584.
43. Decramer M, Molenberghs G, Liu D; For UPLIFT investigators. Respir Med. 2011;105(10):1523-1530.
44. Breekveldt-Postma NS, Koerselman J, Erkens JA, Lammers J W, Herings RM. Enhanced persistence with tiotropium compared with other respiratory drugs in COPD. Respir Med. 2007;101(7):1398-1405.
45. Cramer JA, Bradley-Kennedy C, Scalera A. Treatment persistence and compliance with medications for chronic obstructive pulmonary disease. Can Respir J. 2007;14(1):25-29.
46. Short PM, Williamson PA, Elder DH, Lipworth SI, Schembri S, Lipworth BJ. The impact of tiotropium on mortality and exacerbations when added to inhaled corticosteroids and long-acting β-agonist therapy in COPD. Chest. 2012;141(1):81-86.